These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12438534)

  • 1. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
    Wang X; Dorsam RT; Lauver A; Wang H; Barbera FA; Gibbs S; Varon D; Savion N; Friedman SM; Feuerstein GZ
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1114-20. PubMed ID: 12438534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA; Bozarth JM; Forsythe MS; Slee A
    Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA; Khurana S; Forsythe MS
    Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
    Mousa SA; Abulencia JP; McCarty OJ; Turner NA; Konstantopoulos K
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):552-60. PubMed ID: 11904529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AlphaIIbbeta3 priming and clustering by orally active and intravenous integrin antagonists.
    Hantgan RR; Stahle MC; Connor JH; Connor RF; Mousa SA
    J Thromb Haemost; 2007 Mar; 5(3):542-50. PubMed ID: 17166246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
    Billheimer JT; He B; Spitz SM; Stern AM; Seiffert D
    Thromb Res; 2002 Sep; 107(6):303-17. PubMed ID: 12565717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of clot retraction by glycoprotein IIb/IIIa antagonists.
    Seiffert D; Pedicord DL; Kieras CJ; He B; Stern AM; Billheimer JT
    Thromb Res; 2002 Nov; 108(2-3):181-9. PubMed ID: 12590956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-platelet effects of GPIIb/IIIa and P-selectin antagonism, platelet activation, and binding to neutrophils.
    Caron A; Théorêt JF; Mousa SA; Merhi Y
    J Cardiovasc Pharmacol; 2002 Aug; 40(2):296-306. PubMed ID: 12131559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity.
    Goto S; Tamura N; Li M; Handa M; Ikeda Y; Handa S; Ruggeri ZM
    J Thromb Haemost; 2003 Sep; 1(9):2022-30. PubMed ID: 12941046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct yet complementary mechanisms of heparin and glycoprotein IIb/IIIa inhibitors on platelet activation and aggregation: implications for restenosis during percutaneous coronary intervention.
    Day JR; Malik IS; Weerasinghe A; Poullis M; Nadra I; Haskard DO; Taylor KM; Landis RC
    Heart; 2004 Jul; 90(7):794-9. PubMed ID: 15201252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibition of adenosine diphosphate- versus thrombin receptor-activating peptide-stimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics.
    Weber AA; Schrör K
    Blood; 2001 Sep; 98(5):1619-21. PubMed ID: 11520817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
    Leclerc JR
    Crit Care Med; 2002 May; 30(5 Suppl):S332-40. PubMed ID: 12004256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation.
    Frelinger AL; Furman MI; Barnard MR; Krueger LA; Dae MW; Michelson AD
    Am J Cardiol; 2003 Nov; 92(9):1099-101. PubMed ID: 14583364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
    Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
    Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of shear-stress-induced platelet aggregation and phosphotyrosine signaling by GPIIb-IIIa antagonists.
    Haga JH; Jennings LK; Slack SM
    Ann Biomed Eng; 2002; 30(10):1262-72. PubMed ID: 12540202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.